You just read:

Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency

News provided by

Ascendis Pharma

15 Dec, 2014, 11:00 GMT